## ADVERSE REACTIONS

The most common adverse reactions (â‰¥10% and at a frequency higher than placebo) were: thrombocytopenia, pityriasis, rash, rhinitis, epistaxis, vomiting, and dizziness. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact X4**

**Pharmaceuticals, Inc. at 1-866-MED-X4MI (1-866-633-9464) or FDA at 1-800-FDA-1088 or[ www.fda.gov/medwatch.](http://www.fda.gov/medwatch)**

## DRUG INTERACTIONS

- Strong CYP3A4 inhibitors: Reduce XOLREMDI daily dosage. (2.2,7\.1)
- P-gp inhibitors or moderate CYP3A4 inhibitors: Monitor more frequently for XOLREMDI adverse reactions and reduce XOLREMDI daily dosage if necessary. (7.1)
- Strong CYP3A4 Inducers: Avoid concomitant use. (7.1)
- CYP3A4 or P-gp substrates: Monitor more frequently for substrate adverse reactions unless otherwise recommended. (7.2)

## USE IN SPECIFIC POPULATIONS

- Lactation: Advise females that breastfeeding is not recommended. (8.2)
- Renal Impairment: Not recommended for use in patients with severe renal impairment or end stage renal disease. (8.6)
- Hepatic Impairment: Not recommended for use in patients with moderate to severe hepatic impairment. (8.7)

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 04/2024**
